The combination of radiotherapy (RT) and programmed death 1 inhibitors seems to increase antitumor immune responses.
Objective:
To assess the outcome and the role of the best combination sequence, i.e. immunotherapy given before, during, and/or after RT, in patients with non-small cell lung cancer (NSCLC).
Methods:
We conducted an observational, retrospective analysis of 95 consecutive patients with advanced NSCLC who received any radiotherapy treatment and nivolumab, as clinically indicated. Median overall survival (OS) and the 95% confidence interval (CI) were estimated with the Kaplan-Meier method. Cox model was used to obtain hazard ratio (HR) and associated 95% CI with statistical inference by log-rank statistic.
Results:
Median OS was 11.9 months (95% CI, 6.6–17.2). Patients who received radiotherapy during an immune checkpoint inhibitor treatment started more than 60 days before showed a better outcome than patients who started immunotherapy over 60 days after RT ending (HR, 2.90 [1.37–6.12], p = 0.005; median OS, 22.4 months vs 8.6 months, p = 0.005). Median progression-free survival was 6.3 months (95% CI, 4.6–8.0).
Conclusions:
This study shows that combining irradiation with nivolumab for the treatment of advanced NSCLC leads to improved OS. The optimal time window for the combination of RT and immunotherapy seems to play a critical role for therapeutic antitumor response derived by abscopal effect.
HodiSO’DaySJMcDermottDF, et al. Improved survival with ipilumumab in patients with metastatic melanoma. N Engl J Med2010; 363: 711–723.
2.
BrahmerJReckampKLBassP, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. N Engl J Med2015; 373: 123–135.
3.
BorghaeiHPaz-AresLHornL, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer. N Engl J Med2015; 373: 1627–1639.
4.
HerbstRSBaasPKimDW, et al. Pembrolizumab versus docetaxel for previously treated, PDL1 positive, advanced non small cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet2016; 387: 1540–1550.
5.
AntoniaSJVillegasADanielD, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med2018; 379: 2342–2350.
6.
MotzerRJEscudierBMcDermott, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med2015; 373: 1803–1813.
7.
BellmuntJde WitRVaughnDJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med2017; 376: 1015–1026.
8.
BalarAVGalskyMDRosenbergJE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm multicenter, phase 2 trial. Lancet2017; 389: 67–76.
9.
RosenbergJEHoffman-CensitsJPowlesT, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum -based chemotherapy: a single-arm, multicenter, phase 2 trial. Lancet2016; 387: 1909–1920.
10.
SharmaORetzMSiefker-RadtkeA, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicenter, single arm, phase 2 trial. Lancet Oncol2017; 18: 312–322.
11.
ReganMMWernerLRaoS, et al. Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition: a pooled analysis of patients with advanced melanoma. J Clin Oncol2019; 37: 3350–3358.
12.
KatoSGoodmanAWalavalkarV, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res2017; 23: 4242–4250.
13.
BurnetteBWeichselbaumRR.Radiation as an immune modulator. Semin Radiat Oncol2013; 23: 273–280.
14.
ParkBYeeCLeeKM.The effect of radiation on immune response to cancer. Int J Mol Sci2014; 15: 927–943.
15.
PoppIGrosuALNiedermannG, et al. Immune modulation by hypofractionated stereotactic radiation therapy: therapeutic implications. Radiother Oncol2016; 120:185–194.
16.
MoleRH.Whole body irradiation: radiobiology or medicine?Br J Radiol1953; 26: 234–241.
17.
WalshawRCHoneychurch IllidgeT.Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?Br J Radiol2016; 89: 20160472.
18.
HinikerSMChenDSReddyS, et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol2012; 5: 404–407.
19.
DemariaSPilonesKAVanpouille-BoxC, et al. The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res2014; 182: 170–181.
20.
DengLLiangHBurnetteB, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest2014; 124: 687–695.
21.
SivaSMacManusMPMartinRF, et al. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett2015; 356: 82–90.
22.
ShaverdianNLisgergABornazyanK, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol2017; 18: 895–903.
23.
FormentiSCDe MariaS.Systemic effects of local radiotherapy. Lancet Oncol2009; 10: 718–726.
24.
Vanpouille-BoxCAlardAAryankalayilMJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun2017; 9: 15618.
25.
MatsumuraSWangBKawashimaN, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol2008; 181: 3099–30107.
26.
ChakrabortyMAbramsSIColemanCN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res2004; 64: 4328–4337.
27.
ChakrabortyMAbramsSICamphausenK, et al. Irradiation of tumor cells upregulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol2003; 170: 6338–6347.
28.
ReitsEAHodgeJWHerbertsCA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med2006; 203: 1259–1271.
29.
LugadeAASorensenEWGerberSA, et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol2008; 180: 3132–3139.
30.
LukeJJLemonsJMKarrisonTG, et al. Safety and clinical activity of pembrolizumab and Multisite stereotactic body radiotherapy in Patients with advanced solid tumors. J Clin Oncol2018; 36: 1611–1618.
31.
RiihimakiMHemminkiAFallahM, et al. Metastatic sites and survival in lung cancer. Lung Cancer2014; 86: 78–84.
32.
LandiLD’IncàFGelibterAJ, et al. Bone metastases and efficacy of immunotherapy in patients with pretreated advanced non-small-cell lung cancer (NSCLC). J Immunother Cancer2019; 21: 316.
33.
GabrilovichDIOstrand-RosenbergSBronteV.Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol2012; 12: 253–268.
34.
ReinsteinZZPamarthySSagarV, et al. Overcoming immunosuppression in bone metastases. Crit Rev Oncol Hematol2017; 117: 114–117.
35.
GrossiFCrinòLLogroscinoA, et al. Use of nivolumab in elderly patients with advanced squamous non-small-cell-lung cancer: results from the Italian cohort of an expanded access programme. Eur J Cancer2018; 100: 126e134.
36.
SolanaRTarazonaRGayosoI, et al. Innate immunosenescence: effect of aging on cells and receptors of innate immune system in humans. Semin Immunol2012; 24: 331–341.
37.
PawelecG.Immunosenescence comes of age. Symposium on aging research in immunology: the impact of genomics. EMBO Rep2007; 8: 220–223.
38.
DasteADomblidesCGross-GoupilM, et al. Immune checkpoint inhibitors and elderly people: a review. Eur J Cancer2017; 82: 155–166.
39.
HaynesLEatonSM.The effect of age on the cognate function of CD4+T cells. Immunol Rev2005; 205: 220–228.
40.
SimoneRZiccaASaverinoD.The frequency of regulatory CD3+CD8+CD28−CD25+ T lymphocytes in human peripheral blood increases with age. J Leukoc Biol2008; 84: 1454–1461.
41.
EliasRKarantanosTSiraE, et al. Immunotherapy comes of age: immune aging & checkpoint inhibitors. J Geriatr Oncol2017; 8: 229–235.
42.
TurajlicSLitchfieldKXuH, et al. Insertion-and-deletion-derived tumor-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol2017; 18: 1009–1021.
43.
AntoniaSJVillegasADanielD, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med2017; 377: 1919–1929.
